Ohio is currently home to 3214 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
NCT06096116
Recruiting
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/05/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Acquired Antithrombin Deficiency
Register for Updates
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
NCT06040099
Recruiting
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/05/2025
Locations: Research Site, Columbus, Ohio
Conditions: Hepatocellular Carcinoma (HCC)
Register for Updates
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Xentria Investigative Site, Cincinnati, Ohio
Conditions: Pulmonary Sarcoidosis
Register for Updates
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
NCT05579639
Recruiting
Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population. The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing... Read More
Gender:
ALL
Ages:
Between 4 months and 25 years
Trial Updated:
03/05/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Allogeneic Stem Cell Transplantation
Register for Updates
ALTERRA Post-Approval Study
NCT05378386
Recruiting
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Gender:
ALL
Ages:
All
Trial Updated:
03/05/2025
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Pulmonary Valve Insufficiency, Complex Congenital Heart Defect, Tetralogy of Fallot, Pulmonary Regurgitation, RVOT Anomaly
Register for Updates
Myriad™ Augmented Soft Tissue Reconstruction Registry
NCT05243966
Recruiting
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Abdominal Wound Dehiscence, Necrotizing Soft Tissue Infection, Lower Extremity Wound, Pilonidal Sinus, Anal Fistula, Hidradenitis Suppurativa, Pressure Injury
Register for Updates
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR)... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/05/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04925375
Recruiting
There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID. This study is a multi-site, phase II, randomized, blinded/placebo-controlled clinical trial in pediatric and adult subjects to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID. Fu... Read More
Gender:
ALL
Ages:
4 years and above
Trial Updated:
03/05/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Register for Updates
IV Gallium Study for Patients with Cystic Fibrosis Who Have NTM (ABATE Study)
NCT04294043
Recruiting
The purpose of this study is to assess the safety and tolerability of two 5-day infusion cycles of IV gallium in adult patients with CF who are infected with NTM. Funding Source - FDA Office of Orphan Products Development (OOPD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Nontuberculous Mycobacterium Infection
Register for Updates
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04049669
Recruiting
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors. The central clinical... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/05/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Proton Therapy Patient Registry
NCT02986048
Recruiting
The purpose of this study is to establish a database (or "registry") of patients treated with proton beam therapy at the University Hospitals (UH) Proton Therapy Center. By keeping track of the patients treated it will allow the investigators to periodically evaluate the outcomes of patients.
Gender:
ALL
Ages:
All
Trial Updated:
03/05/2025
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Treatment With Proton Beam Radiation Therapy
Register for Updates
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624
Recruiting
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Neurocrine Clinical Site, Avon Lake, Ohio
Conditions: Major Depressive Disorder
Register for Updates